OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 mrt 2010 - 14:00
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces publication of positive Locteron interim Phase IIb data
Bericht
OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO) announces publication of an abstract containing preliminary Locteron® Phase IIb clinical results. The abstract was submitted by OctoPlus’ licensee Biolex and has been accepted for an oral presentation at the 45th International Liver Congress on 16 April 2010 in Vienna, Austria. This abstract is the first of several publications on Locteron expected around the conference. The presentation at the conference will contain final results after 12 weeks of treatment.
Datum laatste update: 09 mei 2025